Page last updated: 2024-08-24

lissamine rhodamine b and Bile Duct Cancer

lissamine rhodamine b has been researched along with Bile Duct Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kongpetch, S; Kukongviriyapan, V; Prawan, A; Senggunprai, L; Tusskorn, O; Wandee, J	1

Other Studies

1 other study(ies) available for lissamine rhodamine b and Bile Duct Cancer

Article	Year
Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway. Life sciences, 2018, Aug-15, Volume: 207 Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Metformin; Neoplasm Invasiveness; Rhodamines; Signal Transduction; TOR Serine-Threonine Kinases; Wound Healing	2018

Article

Year

Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway.

Life sciences, 2018, Aug-15, Volume: 207

Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Metformin; Neoplasm Invasiveness; Rhodamines; Signal Transduction; TOR Serine-Threonine Kinases; Wound Healing

2018